Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Belzutifan

FDA-approved product (tablet, oral), marketed as Welireg.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Belzutifan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Clear cell renal carcinoma
  • Hemangioblastoma
  • Neoplasm
  • Pancreatic neuroendocrine tumor
  • Renal cell adenocarcinoma
  • Renal cell carcinoma
  • Von Hippel-Lindau disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Hypoxia-inducible Factor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Belzutifan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Belzutifan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    NCT04924075 · start 2021-08-12

    Registered record
    Registry ID
    NCT04924075
    Conditions
    Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor; HIF-2α Mutated Cancers
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-08-12
    Completion
    2029-12-27
    Enrolment
    355

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Advanced Gastrointestinal Stromal Tumor +1 more
    InterventionBelzutifan
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

    NCT04846920 · start 2021-06-14

    Registered record
    Registry ID
    NCT04846920
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-14
    Completion
    2026-04-11
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan
    PhasePhase 1
    Registry statusCompleted

  • A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

    NCT04736706 · start 2021-04-14

    Registered record
    Registry ID
    NCT04736706
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Pembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-04-14
    Completion
    2027-04-22
    Enrolment
    1,854

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionPembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

    NCT04586231 · start 2021-02-25

    Registered record
    Registry ID
    NCT04586231
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan; Lenvatinib; Cabozantinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-02-25
    Completion
    2027-02-11
    Enrolment
    747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan; Lenvatinib; Cabozantinib
    PhasePhase 3
    Registry statusActive not recruiting

  • ABEMA Alone or in COMBO With MK-6482

    NCT04627064 · start 2020-12-31

    Registered record
    Registry ID
    NCT04627064
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    Abemaciclib; MK-6482
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-31
    Completion
    2024-08-04
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionAbemaciclib; MK-6482
    PhasePhase 1
    Registry statusCompleted

  • Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

    NCT04626518 · start 2020-12-17

    Registered record
    Registry ID
    NCT04626518
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Pembrolizumab; MK-4830; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Favezelimab/Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-17
    Completion
    2026-08-21
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionPembrolizumab; MK-4830; Belzutifan; Lenvatinib +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

    NCT04626479 · start 2020-12-16

    Registered record
    Registry ID
    NCT04626479
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Pembrolizumab; Favezelimab/Pembrolizumab; Belzutifan; Lenvatinib; Pembrolizumab/Quavonlimab; Vibostolimab/Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-16
    Completion
    2026-08-21
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionPembrolizumab; Favezelimab/Pembrolizumab; Belzutifan; Lenvatinib +2 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

    NCT04489771 · start 2020-09-13

    Registered record
    Registry ID
    NCT04489771
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-09-13
    Completion
    2026-10-04
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

    NCT04195750 · start 2020-02-27

    Registered record
    Registry ID
    NCT04195750
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-02-27
    Completion
    2026-09-17
    Enrolment
    755

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan; Everolimus
    PhasePhase 3
    Registry statusActive not recruiting

  • A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

    NCT03634540 · start 2018-09-27

    Registered record
    Registry ID
    NCT03634540
    Conditions
    Renal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer; Renal Cell Carcinoma; Renal Cell Cancer Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Cancer, Recurrent; Kidney
    Interventions
    Belzutifan; Cabozantinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-09-27
    Completion
    2027-02-26
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma (RCC); Clear Cell Renal Cell Carcinoma (ccRCC); Kidney Cancer; Renal Cancer +5 more
    InterventionBelzutifan; Cabozantinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

    NCT03401788 · start 2018-05-02

    Registered record
    Registry ID
    NCT03401788
    Conditions
    VHL - Von Hippel-Lindau Syndrome; VHL Gene Mutation; VHL Syndrome; VHL Gene Inactivation; VHL-Associated Renal Cell Carcinoma; VHL-Associated Clear Cell Renal Cell Carcinoma
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-05-02
    Completion
    2027-04-29
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVHL - Von Hippel-Lindau Syndrome; VHL Gene Mutation; VHL Syndrome; VHL Gene Inactivation +2 more
    InterventionBelzutifan
    PhasePhase 2
    Registry statusActive not recruiting

  • A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets

    NCT03445169 · start 2018-02-23

    Registered record
    Registry ID
    NCT03445169
    Conditions
    Healthy
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-23
    Completion
    2018-05-26
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBelzutifan
    PhasePhase 1
    Registry statusCompleted

  • A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

    NCT02974738 · start 2016-12-07

    Registered record
    Registry ID
    NCT02974738
    Conditions
    Advanced Solid Tumors; Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; ccRCC; RCC, Clear Cell Adenocarcinoma; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma, Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Carcinoma, Clear Cell Adenocarcinoma; Glioblastoma; Glioblastoma, Adult; GBM; Glioblastoma Multiforme
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-12-07
    Completion
    2026-10-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors; Solid Tumor; Solid Carcinoma; Solid Tumor, Adult +12 more
    InterventionBelzutifan
    PhasePhase 1
    Registry statusActive not recruiting

  • Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    NCT02861573 · start 2016-11-17

    Registered record
    Registry ID
    NCT02861573
    Conditions
    Metastatic Castration-Resistant Prostate Cancer
    Interventions
    Pembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg; Enzalutamide 160 mg; Dexamethasone 8 mg; Olaparib 300 mg; Abiraterone acetate 1000 mg; Lenvatinib; Pembrolizumab/Vibostolimab coformulation; Carboplatin; Etoposide; Belzutifan 120mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2016-11-17
    Completion
    2028-07-24
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Cancer
    InterventionPembrolizumab 200 mg; Olaparib 400 mg; Docetaxel 75 mg/m^2; Prednisone 5 mg +9 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

    NCT02293980 · start 2014-11-25

    Registered record
    Registry ID
    NCT02293980
    Conditions
    ccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma
    Interventions
    MK-3795; Nivolumab; Cabozantinib; Bezlutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2014-11-25
    Completion
    2026-11-30
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionccRCC; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma +1 more
    InterventionMK-3795; Nivolumab; Cabozantinib; Bezlutifan
    PhasePhase 1
    Registry statusActive not recruiting